Exploiting signal transduction pathways in acute myelogenous leukemia

Current Treatment Options in Oncology

Volumn 8, Issue 4, 2007, Pages 265-276

  Perl, Alexander E ^a   Carroll, Martin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD135 ANTIGEN; CYTARABINE; DASATINIB; DAUNORUBICIN; ETOPOSIDE; EVEROLIMUS; IMATINIB; LESTAURTINIB; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOXANTRONE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SEMAXANIB; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ATAXIA; BIOLOGICAL ACTIVITY; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; EDEMA; FATIGUE; GASTROINTESTINAL IRRITATION; GENE DIRECTED ENZYME PRODRUG THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; POLYDIPSIA; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UREMIA; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; SIGNAL TRANSDUCTION;

EID: 38349062330     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0043-z     Document Type: Review

References (53)

1. Sanz MA et al., A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood, 1999. 94 (9): P. 3015-3021
2. Cassileth PA et al., Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med, 1998. 339 (23): P. 1649-1656
3. Rowe JM et al., A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood, 2004. 103 (2): P. 479-485
4. Slovak ML et al., Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 2000. 96 (13): P. 4075-4083
5. Nakao M et al., Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 1996. 10(12): P. 1911-1918
6. Shen WP et al., Expression of normal and mutant ras proteins in human acute leukemia. Oncogene, 1987, 1(2): P. 157-165
7. Yamamoto Y et al., Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 2001. 97 (8): P. 2434-2439
8. Guzman ML et al., Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 2001. 98 (8): p. 2301-2307
9. Guzman ML et al., Preferential induction of apoptosis for primary human leukemic stem cells. PNAS, 2002. 99 (25): P. 16220-16225
10. Kubota Y et al., Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia, 2004. 18 (8): P. 1438-1440
11. Zhao S et al., Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia, 2004. 18 (2): P. 267-275
12. Xu Q et al., Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003. 102 (3): P. 972-980
13. Grandage VL et al., PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia, 2005. 19 (4): P. 586-594
14. Xu Q, JE Thompson, M Carroll, mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood, 2005. 106 (13): P. 4261-4268
15. Milella M et al., Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest, 2001. 108 (6): P. 851-859
16. Gilliland DG, Jordan CT, Felix CA: The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004:80-97
17. Druker BJ, Imatinib: Paradigm or anomalyP Cell Cycle, 2004. 3 (7): p. 833-835
18. Druker BJ, NB Lydon, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, 2000. 105 (1): P. 3-7 3-7
19. Gilliland DG, JD Griffin, The roles of FLT3 in hematopoiesis and leukemia. Blood, 2002. 100 (5): P. 1532-1542
20. Levis M, D Small, Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Des, 2004. 10 (11): P. 1183-1193
21. Stone RM et al., Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005. 105 (1): P. 54-60
22. DeAngelo DJ et al., Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood, 2006. 108 (12): P. 3674-3681
23. Smith BD et al., Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 2004. 103 (10): P. 3669-3676
24. Fiedler W, et al., A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005. 105 (3): P. 986-993
25. Karbowniczek M, EP Henske, The role of tuberin in cellular differentiation: Are B-Raf and MAPK involved? Ann N Y Acad Sci 2005. 1059: P. 168-173
26. Piloto O, et al.: Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2006
27. Gorre ME et al., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001. 293 (5531): P. 876-880
28. Heidel F et al., Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood, 2006. 107 (1): P. 293-300
29. Levis M et al., Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood, 2006. 108 (10): P. 3477-3483
30. Stone RM et al., Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (da) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood (ASH Annual Meeting Abstracts), 2006. 108 (11): P. 157
31. DeAngelo DJ, et al.: Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2006, 108(11): 158
32. Levis M et al., A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition. Blood, 2005. 106 (11): P. 121a
33. Karp JE et al., Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood, 2001. 97 (11): P. 3361-3369
34. Harousseau JL et al., A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood, 2007. 109 (12): P. 5151-5156
35. Lancet JE et al., A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007. 109 (4): P. 1387-1394
36. Fenaux P et al., A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood, 2007. 109 (10): P. 4158-4163
37. Zhu K et al., Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood, 2005. 105 (12): P. 4759-4766
38. Liu G et al., Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336). Anticancer Drugs, 2007. 18 (8): P. 923-931
39. Karp JE, et al.: Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia (AML): Phase I trial of oral tipifarnib (T) combined with oral etoposide (E) for adults ≥ 70 who are not candidates for traditional cytotoxic chemotherapy (TCC). ASH Annual Meeting Abstracts 2006, 108(11): 426
40. Recher C et al., Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005. 105 (6): P. 2527-2534
41. Yee KW et al., Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res, 2006. 12 (17): P. 5165-5173
42. Yee KWL et al., A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias. Blood (ASH Annual Meeting Abstracts), 2004. 104 (11): P. 4523a
43. Zeng Z, et al.: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2006
44. Luger S, et al.: A phase I dose escalation study of the mTOR inhibitor sirolimus and MEC chemotherapy targeting signal transduction in leukemic stem cells for acute myeloid leukemia. ASH Annual Meeting Abstracts 2006, 108(11): 161
45. Mrozek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2006:169-177
46. Paschka P et al., Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol, 2006. 24 (24): P. 3904-3911
47. Kindler T et al., Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood, 2004. 103 (10): P. 3644-3654
48. Kindler T et al., Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood, 2003. 101 (8): P. 2960-2962
49. Cortes J et al., Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003. 97 (11): P. 2760-2766
50. Aguayo A et al., Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999. 94 (11): P. 3717-3721
51. Hussong JW, GM Rodgers, PJ Shami, Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 2000. 95 (1): P. 309-313
52. Roboz GJ et al., Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 2006. 20 (6): P. 952-957
53. Karp JE et al., Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta- d -arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res, 2004. 10 (11): P. 3577-3585